Oct 2026· Immunotherapy· pp.
1-12
· 0 citations· 27 references
Medicine
TL;DR
Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.
Abstract
Aim
To evaluate the real‑world efficacy and safety of adding programmed cell death protein 1 (PD-1) inhibitors to neoadjuvant chemotherapy in Chinese patients with triple‑negative breast cancer (TNBC).
PATIENTS AND
Methods
This single-center retrospective study enrolled 218 TNBC patients receiving neoadjuvant therapy, including 116 in the neoadjuvant chemotherapy (NAC) cohort and 102 in the neoadjuvant immunochemotherapy (NAIC) cohort. Clinical, biological, pathological and therapeutic data were collected. Primary endpoints were pathological complete response (pCR) and event-free survival (EFS).
Results
Multivariate analysis showed Ki-67 >30% (p = 0.003) and PD-1 inhibitor addition (p < 0.001) were independently associated with higher pCR. NAIC significantly reduced recurrence (7.8% vs. 25.0%, p < 0.001). Miller-Payne grades 2-4 were independent prognostic factors for improved EFS compared with grade 1 (all p < 0.05); grade 5 was excluded due to collinearity with pCR. Except for immune-related adverse events (irAEs), the incidence of other adverse events (AEs) showed no significant differences between the two groups (all p > 0.05).
Conclusions
Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.
556
Background:
While clinical trials report subtype-specific pathologic complete response (pCR) rates, real-world data from safety-net health systems remain limited and underrepresented in major neoadjuvant trials. Our urban safety-net patient population in Oakland, CA, provides a unique view of real-world neo...
Nancy T. Nguyen, Chun-Yin Chow, Nguyen Nguyen et al.· JCO Oncology Practice· 0 citations
Objective: To evaluate the impact of incorporating platinum-based agents into neoadjuvant chemotherapy regimens on achieving pathological complete response in patients with triple-negative breast cancer.
Method: The retrospective, cohort study was conducted in March 2025 at the Dow University Hospital, Karachi, and com...
Rutaba Alam, Omema Saleem, Maryum Nouman et al.· JOURNAL OF PAKISTAN MEDICAL...· 0 citations
Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.
Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al.· Frontiers in Oncology· 0 citations
NICT was associated with improved survival compared with either NCT or CCRT, and these findings are hypothesis-generating and require prospective validation.
Run-Zhi Wang, Cheng-Xian Ma, Huan-Wei Liang et al.· Digestive and Liver Disease· 0 citations
Introduction: Locally advanced breast cancer (LABC) is associated with high morbidity. While neoadjuvant chemotherapy (NAC) is the standard of care, clinical responses vary significantly due to tumor heterogeneity. This study evaluated pre-treatment intracellular Interleukin-33 (IL-33) expression as an independent pred...
Rachmad Meyliandry Putra, Nilam Smaradhania, Indra Indra et al.· Asian Pacific Journal of Can...· 0 citations